S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:BLFS

BioLife Solutions - BLFS Stock Forecast, Price & News

$24.59
+0.99 (+4.19%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.68
$25.00
50-Day Range
$12.99
$24.59
52-Week Range
$10.40
$60.67
Volume
291,011 shs
Average Volume
418,981 shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.17

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.5% Upside
$42.17 Price Target
Short Interest
Bearish
6.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of BioLife Solutions in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$337,266 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.67) to ($0.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

626th out of 1,117 stocks

Electromedical Equipment Industry

13th out of 24 stocks

BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Analyst Ratings Changes

Several equities analysts have issued reports on BLFS shares. Oppenheimer raised shares of BioLife Solutions from a "market perform" rating to an "outperform" rating in a report on Monday, April 25th. Cowen reduced their target price on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. Maxim Group reduced their target price on shares of BioLife Solutions from $60.00 to $30.00 in a research report on Thursday, May 12th. Cowen reduced their target price on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. Finally, B. Riley reduced their target price on shares of BioLife Solutions from $48.00 to $34.00 in a research report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.17.

BioLife Solutions Trading Up 4.2 %

BioLife Solutions stock traded up $0.99 during midday trading on Friday, hitting $24.59. 291,011 shares of the stock were exchanged, compared to its average volume of 418,981. BioLife Solutions has a fifty-two week low of $10.40 and a fifty-two week high of $60.67. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -10.93 and a beta of 1.99. The stock's 50-day simple moving average is $16.82 and its 200 day simple moving average is $18.79. The company has a current ratio of 3.55, a quick ratio of 2.53 and a debt-to-equity ratio of 0.02.

BioLife Solutions (NASDAQ:BLFS - Get Rating) last released its quarterly earnings data on Monday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). BioLife Solutions had a negative return on equity of 7.54% and a negative net margin of 64.09%. The firm had revenue of $36.22 million for the quarter, compared to analyst estimates of $37.87 million. During the same quarter in the previous year, the business posted $0.01 earnings per share. On average, equities analysts anticipate that BioLife Solutions will post -0.67 EPS for the current year.

Insider Buying and Selling

In related news, COO Greef Roderick De sold 9,158 shares of the firm's stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total transaction of $144,604.82. Following the completion of the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other BioLife Solutions news, COO Greef Roderick De sold 9,158 shares of BioLife Solutions stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total transaction of $144,604.82. Following the completion of the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CRO Marcus Schulz sold 4,600 shares of BioLife Solutions stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now owns 36,218 shares of the company's stock, valued at $725,446.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,602 shares of company stock worth $330,022. Insiders own 3.30% of the company's stock.

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

BioLife Solutions (NASDAQ:BLFS) Trading 14.5% Higher
BioLife Solutions (BLFS) Scheduled to Post Earnings on Tuesday
BioLife Solutions Inc. News
BioLife Solutions, Inc. (BLFS)
BioLife Solutions Tops Q1 EPS by 8c
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
11/11/2021
Today
8/12/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.17
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+71.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-7,640,000.00
Pretax Margin
-71.64%

Debt

Sales & Book Value

Annual Sales
$119.16 million
Book Value
$9.68 per share

Miscellaneous

Free Float
41,010,000
Market Cap
$1.04 billion
Optionable
Not Optionable
Beta
1.99














BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2022?

6 Wall Street analysts have issued 12-month price targets for BioLife Solutions' stock. Their BLFS share price forecasts range from $30.00 to $65.00. On average, they expect the company's share price to reach $42.17 in the next twelve months. This suggests a possible upside of 70.9% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2022?

BioLife Solutions' stock was trading at $37.27 on January 1st, 2022. Since then, BLFS stock has decreased by 33.8% and is now trading at $24.67.
View the best growth stocks for 2022 here
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) posted its quarterly earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.02 by $0.21. The medical equipment provider had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.65 million. BioLife Solutions had a negative net margin of 64.09% and a negative trailing twelve-month return on equity of 7.54%. During the same quarter last year, the company earned ($0.02) earnings per share.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$166.00 million, compared to the consensus revenue estimate of $163.00 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geneva Capital Management LLC (3.43%), Gagnon Securities LLC (1.35%), TimesSquare Capital Management LLC (1.15%), Zweig DiMenna Associates LLC (1.10%), Jennison Associates LLC (1.08%) and JPMorgan Chase & Co. (1.07%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $24.67.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $1.05 billion and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

How many employees does BioLife Solutions have?

The company employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.